Michael Mix

Dr. Michael Mix

Department of Nuclear Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2001 in Radiology
Verified
Journal Article
Closed access
MRMichael J. Reinhardt
Michael J. Reinhardt
CEClaudia Ehritt-Braun
Claudia Ehritt-Braun
DVDagmar Vogelgesang
Dagmar Vogelgesang
CIChristian Ihling
Christian Ihling
SHStefan Högerle
Stefan Högerle
TKThomas M. Krause
Thomas M. Krause
To compare the diagnostic accuracy of magnetic resonance (MR) imaging with that of positron emission tomography (PET) with 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG) for detecting metastatic lymph nodes in patients with cervical cancer. Before radical hysterectomy and pelvic lymphadenectomy in 35 patients with International Federation of Gynecology and Obstetrics stage IB or II cervical cancer, abdominal FDG-PET and MR imaging were performed. Malignancy criteria were a lymph node diameter of 1 cm or more at MR imaging and a focally increased FDG uptake at PET. The findings of FDG-PET and MR imaging were compared with histologic findings. Histologic examination revealed pN0-stage cancer in 24 patients and pN1-stage cancer in 11 patients. On a patient basis, node staging resulted in sensitivities of 0.91 with FDG-PET and 0.73 with MR imaging and specificities of 1.00 with FDG-PET and 0.83 with MR imaging. The positive predictive value (PPV) of FDG-PET was 1.00 and that of MR imaging, 0.67 (not significant). The metastatic involvement of lymph node sites was identified at FDG-PET with a PPV of 0.90; at MR imaging, 0.64 (P <.05, Fisher exact test). Metabolic imaging with FDG-PET is an alternative to morphologic MR imaging for detecting metastatic lymph nodes in patients with cervical cancer.

17 July 2004 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
IBI. Brink
I. Brink
TST. Schumacher
T. Schumacher
MMMichael Mix
Michael Mix
SRS. Ruhland
S. Ruhland
ESE. Stoelben
E. Stoelben
ENE. U. Nitzsche
E. U. Nitzsche

1 April 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
UNUrsula Nestle
Ursula Nestle
TSTanja Schimek-Jasch
Tanja Schimek-Jasch
SKStephanie Kremp
Stephanie Kremp
ASAndrea Schaefer-Schuler
Andrea Schaefer-Schuler
MMMichael Mix
Michael Mix
BKB Krause
B Krause

1 January 2017 in Theranostics
Verified
Journal Article
Open access
Constantinos ZamboglouConstantinos Zamboglou
Constantinos Zamboglou
VDVanessa Drendel
Vanessa Drendel
CJCordula A. Jilg
Cordula A. Jilg
HRHans C. Rischke
Hans C. Rischke
TBTeresa I. Beck
Teresa I. Beck
AGAnca L. Grosu
Anca L. Grosu
Purpose: The exact detection and delineation of the intraprostatic tumour burden is crucial for treatment planning in primary prostate cancer (PCa). We compared 68Ga-HBED-CC-PSMA PET/CT with multiparametric MRI (mpMRI) for diagnosis and tumour delineation in patients with primary PCa based on slice by slice correlation with histopathological reference material.

1 May 2005 in JACC
Verified
Journal Article
Closed access
TSThomas H. Schindler
Thomas H. Schindler
ENEgbert U. Nitzsche
Egbert U. Nitzsche
HSHeinrich R. Schelbert
Heinrich R. Schelbert
MOManfred Olschewski
Manfred Olschewski
JSJames Sayre
James Sayre
USUlrich Solzbach
Ulrich Solzbach

1 January 2019 in Theranostics
Verified
Journal Article
Open access
Constantinos ZamboglouConstantinos Zamboglou
Constantinos Zamboglou
MCMontserrat Carles
Montserrat Carles
TFTobias Fechter
Tobias Fechter
SKSelina Kiefer
Selina Kiefer
KRKathrin Reichel
Kathrin Reichel
AGAnca L. Grosu
Anca L. Grosu
Purpose: To evaluate the performance of radiomic features (RF) derived from PSMA PET for intraprostatic tumor discrimination and non-invasive characterization of Gleason score (GS) and pelvic lymph node status.